ValuEngine upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a hold rating to a buy rating in a report published on Monday morning, ValuEngine reports.
Other equities analysts have also issued reports about the company. Needham & Company LLC reaffirmed a buy rating and issued a $74.00 price objective on shares of G1 Therapeutics in a research note on Thursday, December 12th. HC Wainwright reiterated a buy rating and issued a $82.00 target price (up from $72.00) on shares of G1 Therapeutics in a report on Tuesday, January 21st. Zacks Investment Research downgraded shares of G1 Therapeutics from a hold rating to a sell rating in a research report on Wednesday, January 8th. BTIG Research raised their price target on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a buy rating in a report on Tuesday, January 7th. Finally, BidaskClub upgraded shares of G1 Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a sell rating and eight have issued a buy rating to the company. G1 Therapeutics presently has a consensus rating of Buy and a consensus target price of $61.43.
Shares of GTHX stock traded down $0.09 on Monday, hitting $19.06. The company had a trading volume of 18,785 shares, compared to its average volume of 239,038. The firm has a market cap of $719.32 million, a P/E ratio of -6.41 and a beta of 2.31. The stock’s 50-day moving average is $23.61 and its two-hundred day moving average is $26.61. The company has a debt-to-equity ratio of 0.03, a quick ratio of 14.28 and a current ratio of 14.28. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $41.80.
Institutional investors have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of G1 Therapeutics by 18.8% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,166 shares of the company’s stock valued at $97,000 after purchasing an additional 500 shares during the period. Victory Capital Management Inc. grew its stake in G1 Therapeutics by 12.9% during the fourth quarter. Victory Capital Management Inc. now owns 4,646 shares of the company’s stock worth $123,000 after purchasing an additional 531 shares during the period. California State Teachers Retirement System increased its holdings in G1 Therapeutics by 1.3% in the third quarter. California State Teachers Retirement System now owns 52,765 shares of the company’s stock worth $1,202,000 after purchasing an additional 671 shares in the last quarter. Swiss National Bank increased its holdings in G1 Therapeutics by 2.2% in the fourth quarter. Swiss National Bank now owns 50,200 shares of the company’s stock worth $1,327,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in G1 Therapeutics by 43.7% in the fourth quarter. Bank of Montreal Can now owns 4,264 shares of the company’s stock worth $113,000 after purchasing an additional 1,296 shares in the last quarter. Hedge funds and other institutional investors own 76.68% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More: What is a Buy-Side Analyst?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.